Murck Harald, Fava Maurizio, Cusin Cristina, Fatt Cherise Chin, Trivedi Madhukar
Dept. of Psychiatry and Psychotherapy, Philipps-University Marburg, Marburg, Germany.
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Brain Behav Immun Health. 2023 Dec 20;35:100717. doi: 10.1016/j.bbih.2023.100717. eCollection 2024 Feb.
Recent observations suggest a role of the volume of the cerebral ventricle volume, corpus callosum (CC) segment volume, in particular that of the central-anterior part, and choroid plexus (CP) volume for treatment resistance of major depressive disorder (MDD). An increased CP volume has been associated with increased inflammatory activity and changes in the structure of the ventricles and corpus callosum. We attempt to replicate and confirm that these imaging markers are associated with clinical outcome in subjects from the EMBARC study, as implied by a recent pilot study. The EMBARC study is a placebo controlled randomized study comparing sertraline vs. placebo in patients with MDD to identify biological markers of therapy resistance. Association of baseline volumes of the lateral ventricles (LVV), choroid plexus volume (CPV) and volume of segments of the CC with treatment response after 4 weeks treatment was evaluated. 171 subjects (61 male, 110 female) completed the 4 week assessments; gender and age were taken into account for this analyses. As previously reported, no treatment effect of sertraline vs. placebo was observed, therefore the study characterized prognostic markers of response in the pooled population. Change in depression severity was identified by the ratio of the Hamilton-Depression rating scale 17 (HAMD-17) at week 4 divided by the HAMD-17 at baseline (HAMD-17 ratio). Volumes of the lateral ventricles and choroid plexi were positively correlated with the HAMD-17 ratio, indication worse outcome with larger ventricles and choroid plexus volumes, whereas the volume of the central-anterior corpus callosum was negatively correlated with the HAMD-17 ratio. Responders (n = 54) had significantly smaller volumes of the lateral ventricles and CP compared to non-responders (n = 117), whereas the volume of mid-anterior CC was significantly larger compared to non-responders (n = 117), confirming our previous findings. In an exploratory way associations between enlarged LVV and CPV and signs of lipid dysregulation were observed. In conclusion, we confirmed that volumes of lateral ventricles, choroid plexi and the mid-anterior corpus callosum are associated with clinical improvement of depression and may be indicators of metabolic/inflammatory activity.
最近的观察结果表明,脑室体积、胼胝体(CC)节段体积,尤其是中央前部的体积,以及脉络丛(CP)体积在重度抑郁症(MDD)的治疗抵抗中发挥作用。CP体积增加与炎症活动增加以及脑室和胼胝体结构变化有关。正如最近一项初步研究所暗示的,我们试图复制并确认这些影像学标志物与EMBARC研究受试者的临床结局相关。EMBARC研究是一项安慰剂对照随机研究,比较舍曲林与安慰剂对MDD患者的疗效,以确定治疗抵抗的生物学标志物。评估了外侧脑室(LVV)基线体积、脉络丛体积(CPV)和CC节段体积与4周治疗后治疗反应的相关性。171名受试者(61名男性,110名女性)完成了4周评估;该分析考虑了性别和年龄。如先前报道,未观察到舍曲林与安慰剂的治疗效果差异,因此该研究确定了合并人群中反应的预后标志物。通过第4周汉密尔顿抑郁量表17项(HAMD - 17)与基线时HAMD - 17的比值(HAMD - 17比值)来确定抑郁严重程度的变化。外侧脑室和脉络丛的体积与HAMD - 17比值呈正相关,表明脑室和脉络丛体积越大,结局越差,而中央前部胼胝体的体积与HAMD - 17比值呈负相关。与无反应者(n = 117)相比,反应者(n = 54)的外侧脑室和CP体积明显更小,而中前部CC的体积明显更大,证实了我们之前的发现。以探索性方式观察到扩大的LVV和CPV与脂质代谢失调迹象之间的关联。总之,我们证实外侧脑室、脉络丛和中前部胼胝体的体积与抑郁症的临床改善相关,可能是代谢/炎症活动的指标。